Evidence map›Paper›PMID 35808003›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Liposomal Form of 2,4-Dinitrophenol Lipophilic Derivatives as a Promising Therapeutic Agent for ATP Synthesis Inhibition.

Kseniya Yu Vlasova, Petr Ostroverkhov, Daria Vedenyapina, Tamara Yakimova, Alla Trusova, Galina Yurievna Lomakina, Stepan Sergeevich Vodopyanov, Mikhail Grin, Natalia Klyachko, Vladimir Chekhonin and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Kseniya Yu VlasovaDepartment of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia.ORCID 0000-0003-3774-1323
Petr OstroverkhovDepartment of Chemistry and Technology of Biologically Active Compounds, Medical and Organic Chemistry, Lomonosov Institute of Fine Chemical Technologies MIREA-Russian Technological University (RTU MIREA), 119571 Moscow, Russia.ORCID 0000-0001-5778-4510
Daria VedenyapinaDepartment of Chemistry and Technology of Biologically Active Compounds, Medical and Organic Chemistry, Lomonosov Institute of Fine Chemical Technologies MIREA-Russian Technological University (RTU MIREA), 119571 Moscow, Russia.
Tamara YakimovaFaculty of Materials Science, Lomonosov Moscow State University, 119991 Moscow, Russia.
Alla TrusovaFaculty of Materials Science, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0001-7294-0964
Galina Yurievna LomakinaSchool of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-8156-0848
Stepan Sergeevich VodopyanovCollege of New Materials and Nanotechnologies, National University of Science and Technology (MISIS), 119049 Moscow, Russia.ORCID 0000-0003-1429-9835
Mikhail GrinDepartment of Chemistry and Technology of Biologically Active Compounds, Medical and Organic Chemistry, Lomonosov Institute of Fine Chemical Technologies MIREA-Russian Technological University (RTU MIREA), 119571 Moscow, Russia.
Natalia KlyachkoSchool of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Vladimir ChekhoninDepartment of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia.
Maxim AbakumovDepartment of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia.ORCID 0000-0003-2622-9201
Lomonosov Moscow State University · RUMIREA - Russian Technological University · RUNational University of Science and Technology · RUPirogov Russian National Research Medical University · RU

Funding

the Russian Science Foundation 20-73-00333
6 · The paper itself

Abstract

Mitochondrial uncoupler 2,4-dinitrophenol (2,4-DNP) is a promising antidiabetic and antiobesity agent. Its clinical use is limited by a narrow dynamic range and accumulation in non-target sensitive organs, which results in whole-body toxicity. A liposomal formulation could enable the mentioned drawbacks to be overcome and simplify the liver-targeted delivery and sustained release of 2,4-DNP. We synthesized 2,4-DNP esters with carboxylic acids of various lipophilic degrees using carboxylic acid chloride and then loaded them into liposomes. We demonstrated the effective increase in the entrapment of 2,4-DNP into liposomes when esters were used. Here, we examined the dependence of the sustained release of 2,4-DNP from liposomes on the lipid composition and LogP

Indexed as

2,4-dinitrophenolATP synthesis inhibitionliposomesmitochondrial uncouplernon-alcoholic fatty liver diseaseobesity

Identifiers

PMID35808003
PMCPMC9268429
OpenAlexW4283368935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.